← Back to Home

Post hoc analysis signals efficacy for lupus drug, but new assessment measure still needs validation

A reanalysis of Phase III dapirolizumab pegol data using a new measure found improvement in active disease manifestations in more patients. However, this new measure of efficacy still needs validation, and the results cannot replace the trial’s prespecified endpoints.

By SURL BioNews

For patients with systemic lupus erythematosus, joint and skin disease may fluctuate independently. Translating improvements across different parts of the body into a reliable assessment of efficacy has long been a challenge in drug research. On November 9, UCB and Biogen announced a new analysis: assessed using an alternative measure, Phase III trial data showed a higher treatment response rate with the investigational drug dapirolizumab pegol, putting the question of how to measure improvement at the center of these findings.

The data, presented at the American College of Rheumatology annual meeting, ACR Convergence 2026, came from a post hoc analysis of the PHOENYCS GO trial. Both groups received standard therapy, with either the investigational drug or placebo added. Using the new measure at week 48, the proportions achieving clinically meaningful improvement in at least half of their active disease domains were 61.2% and 43.2%, respectively—a difference of 18 percentage points. The proportions showing improvement in all active domains were 52.5% and 36.8%.

The assessment tool, called TRM-SLE, was developed by an international working group led by Monash University. It assesses treatment response in each of a patient’s existing active disease manifestations. Patients in this analysis primarily had joint and mucocutaneous involvement, so the data provide more direct insights into these manifestations. They cannot be used to infer that the same degree of benefit would occur across all types of organ involvement.

Another post hoc analysis focused on whether disease control could be maintained. The proportions of patients who achieved low disease activity at all three visits at weeks 40, 44, and 48 were 24.0% in the drug group and 10.3% in the placebo group. The proportions meeting the DORIS definition of remission at all three visits were 11.5% and 4.7%, respectively. Grafa’s coverage of the same announcement also summarized these signals of sustained disease control, but “sustained” here refers only to the trial’s final three assessments and does not yet establish efficacy over multiple years.

These new analyses build on existing trial results. PHOENYCS GO previously met its prespecified primary efficacy endpoint of BICLA response at week 48, with response rates of approximately 50% and 35% in the two groups. Reexamining the data using TRM-SLE offers a complementary way to understand treatment response. Because the measures use different assessment criteria, the higher percentages cannot be interpreted as a further increase in the drug’s efficacy.

Safety also needs to be considered alongside efficacy. Both UCB’s announcement and Grafa reported a higher proportion of patients with treatment-emergent adverse events in the drug group, but fewer serious adverse events. These findings in differing directions cannot be reduced to a conclusion that the drug is safer, nor can all events occurring during treatment be directly attributed to the drug.

Dapirolizumab pegol modulates immune responses by inhibiting CD40L signaling. It remains an investigational biologic in Phase III development and has not been approved by any health authority. The researchers also explicitly stated that TRM-SLE requires further validation; its use in this analysis was neither a prespecified trial endpoint nor part of a regulatory submission. These data provide another perspective on efficacy, while further research is needed to determine whether the new measure can consistently identify improvements that are meaningful to patients.

References

  1. UCB
  2. Grafa